MX2022005308A - Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo. - Google Patents

Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo.

Info

Publication number
MX2022005308A
MX2022005308A MX2022005308A MX2022005308A MX2022005308A MX 2022005308 A MX2022005308 A MX 2022005308A MX 2022005308 A MX2022005308 A MX 2022005308A MX 2022005308 A MX2022005308 A MX 2022005308A MX 2022005308 A MX2022005308 A MX 2022005308A
Authority
MX
Mexico
Prior art keywords
ceacam1
antibody
fragment
specifically binds
same
Prior art date
Application number
MX2022005308A
Other languages
English (en)
Inventor
Hye In Yum
Mi-Young Oh
Jae-Chul Lee
Hye Young Park
Dong-Sik Kim
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2022005308A publication Critical patent/MX2022005308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un epítopo estérico de CEACAM1 y un anticuerpo anti-CEACAM1, o un fragmento del mismo, que se une específicamente al mismo. Un epítopo estérico de CEACAM1, de la presente invención, comprende todos los aminoácidos en posiciones críticas para la unión específica a un anticuerpo anti-CEACAM1 y mantiene una estructura tridimensional apropiada y, por lo tanto, puede tener una alta afinidad por un anticuerpo anti-CEACAM1. Además, un anticuerpo, o un fragmento del mismo, que se une específicamente a un epítopo estérico, de conformidad con la presente invención, puede suprimir eficazmente la interacción CEACAM1-CEACAM1 y la interacción CEACAM1-CEACAM6.
MX2022005308A 2019-11-07 2019-11-07 Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo. MX2022005308A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/015080 WO2021090985A1 (ko) 2019-11-07 2019-11-07 Ceacam1의 입체 에피토프 및 이에 특이적으로 결합하는 항-ceacam1 항체 또는 이의 단편

Publications (1)

Publication Number Publication Date
MX2022005308A true MX2022005308A (es) 2022-05-26

Family

ID=75848522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005308A MX2022005308A (es) 2019-11-07 2019-11-07 Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo.

Country Status (7)

Country Link
US (1) US20220289819A1 (es)
JP (1) JP2023501387A (es)
AU (1) AU2019473233A1 (es)
BR (1) BR112022008774A2 (es)
CA (1) CA3158635A1 (es)
MX (1) MX2022005308A (es)
WO (1) WO2021090985A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100033002A1 (it) * 2021-12-29 2023-06-29 Diatheva S R L Anticorpi umani e loro usi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CA2892371C (en) * 2011-12-01 2021-01-19 The Brigham And Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
MX366359B (es) * 2014-04-27 2019-07-05 Ccam Biotherapeutics Ltd Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
WO2016120331A1 (de) * 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
KR102325944B1 (ko) * 2017-11-30 2021-11-12 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도

Also Published As

Publication number Publication date
AU2019473233A1 (en) 2022-04-14
CA3158635A1 (en) 2021-05-14
WO2021090985A1 (ko) 2021-05-14
JP2023501387A (ja) 2023-01-18
BR112022008774A2 (pt) 2022-07-26
US20220289819A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
PH12018501284A1 (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
WO2020037150A3 (en) Engineered bispecific proteins
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MX358739B (es) Proteinas de union a amiloide beta.
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
MY155144A (en) NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
MX2023000962A (es) Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022016192A (es) Anticuerpos anti-nectina-4 condicionalmente activos.
SG10201801219VA (en) Anti-HER2 Antibodies
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2022009150A (es) Anticuerpos multiespecificos, composiciones que los comprenden, y vectores y usos de los mismos.
MX2022005308A (es) Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo.
MX2022016322A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
MX2019003908A (es) Metodo por multiproteasa.
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
MX2021016066A (es) Anticuerpos heterodimericos que se unen a cd38 y cd3.
WO2019078697A3 (ko) 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.